Initial Beneficial Ownership · 3/A
Attovia Therapeutics, Inc.
Initial Beneficial Ownership
Structured filing — 3/A
form3a-10082026_111047.xml
Amendment · This filing reports the amendment as submitted.
Filing details
- Report period
- 2026-08-04
- Original submission
- 2026-08-04
- Issuer
- Attovia Therapeutics, Inc.
- Issuer CIK
- 0002058707
- Trading symbol
- ATTO
Reporting owner 1
- Name
- Chan Steven
- Reporting owner CIK
- 0001654907
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O ATTOVIA THERAPEUTICS, INC., 1091 INDUSTRIAL ROAD, SUITE 310, SAN CARLOS, CA, 94070
Derivative holdings
| Security | Conversion / exercise price | Exercisable | Expires | Underlying security | Underlying shares | Ownership |
|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 3.5302 | [F1] | 2034-11-13 | Common Stock | 215,285 | D |
| Stock Option (Right to Buy) | 4.9237 | [F2] | 2035-05-17 | Common Stock | 80,731 | D |
Table key
- D
- Direct
Footnotes
- F1
- The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on October 14, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.↩ 1
- F2
- The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 18, 2026, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.↩ 1
Remarks
This Form 3 amendment amends the Form 3 filed on August 4, 2026, which reported the Reporting Person's beneficial ownership using the Issuer's CIK number. This Form 3 amendment has been filed under the Reporting Person's CIK and reflects him as the Reporting Person. This filing amends and replaces the original filing in its entirety. No changes have been made or are being reported with respect to the Reporting Person's beneficial ownership of the Issuer's securities.
Signature 1
- Signed
- /s/ Steven Chan
- Date
- 2026-10-08
Filed exhibits
- EX-24 ↗ex24-10082026_111048.htm
Company context
We are a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. Our lead pipeline candidates target commercially validated pathways and are designed through our ATTOBODY biologics platform to deliver improved treatments relative to the current standards of care. Leveraging our ATTOBODY platform, we have nominated three product candidates within our first two years, including one currently in the clinic, ATTO-1310. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31 (IL-31) that completed dosing in a Phase 1 clinical trial in healthy volunteers (HVs) and patients in the first quarter of 2026. ATTO-2306 is an ATTOBODY-based bispecific targeting interleukin-13 (IL-13) and IL-31 that is in investigational new drug (IND)-enabling studies, and we expect to commence a Phase 1 clinical trial in the first half of 2027. Lastly, ATTO-1091 is our trispecific ATTOBODY-based Fc fusion protein that is designed to block TL1A, IL-23 and integrin a4ß7 simultaneously, and is currently in IND-enabling studies.